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Abstract
Thiazide diuretics, commonly used antihypertensives, may cause QT interval (QT) prolongation, a 
risk factor for highly fatal and difficult to predict ventricular arrhythmias. We examined whether 
common SNPs modified the association between thiazide use and QT or its component parts (QRS 
interval, JT interval) by performing ancestry-specific, trans-ethnic, and cross-phenotype genome-
wide analyses of European (66%), African American (15%), and Hispanic (19%) populations 
(N=78,199), leveraging longitudinal data, incorporating corrected standard errors to account for 
underestimation of interaction estimate variances and evaluating evidence for pathway enrichment. 
Although no loci achieved genome-wide significance (P<5×10−8), we found suggestive evidence 
(P<5×10−6) for SNPs modifying the thiazide-QT association at 22 loci, including ion transport loci 
(e.g. NELL1, KCNQ3). The biologic plausibility of our suggestive results and simulations 
demonstrating modest power to detect interaction effects at genome-wide significant levels 
indicate that larger studies and innovative statistical methods are warranted in future efforts 
evaluating thiazide-SNP interactions.
Over the past decade, the use of prescription drugs has skyrocketed, with nearly half of all 
Americans now taking at least one prescription drug.(1) Accompanying the increased 
prevalence of drug use is a high burden of adverse drug reactions (ADRs), which account for 
approximately 100,000 deaths and 2.2 million serious health effects annually.(2–4) QT 
interval (QT) prolongation, which can trigger fatal ventricular arrhythmias, is a long-
recognized adverse effect(5) of numerous common medications, such as antipsychotics, 
antibiotics, antiarrhythmics, and antihypertensives.(6) Within the past ten years, QT 
prolongation has represented the most common cause for withdrawal of a drug from the 
market (or relabeling) after approval by the U.S. Food and Drug Administration (FDA).(7, 8) 
However, drug-induced QT prolongation remains difficult to predict.(9)
Genetic variants are known to mediate both pharmacokinetic and pharmacodynamic 
processes, thereby playing a major role in drug response. (10) Pharmacogenomics, which 
evaluates the role of genetics in drug response, offers a promising avenue for understanding 
variation in drug response,(11) illuminating novel pathways, informing drug development 
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and selection,(12–14) optimizing dosing regimens,(15–19) and avoiding ADRs.(20–22) QT 
is highly heritable (35–40%).(23–27) Previous pharmacogenomics studies of drugs 
associated with QT prolongation, including thiazide diuretics, a common antihypertensive 
therapy used by over a quarter of the U.S. hypertensive population,(28) identified multiple 
loci associated with anti-hypertensive response and ADRs.(29–34) Furthermore, thiazide 
diuretics are used unequally across race/ethnic groups in the U.S., with approximately 10% 
of Hispanic/Latinos, 13% of European Americans, and 23% of African Americans taking a 
thiazide diuretic.(28, 35, 36) Therefore, the pharmacogenomics of thiazide-induced QT 
prolongation represents an excellent but understudied candidate for pharmacogenomic 
inquiry.
We previously examined evidence for common single nucleotide polymorphisms (SNPs) 
that modified the association between thiazide use and QT and failed to identify any 
genome-wide significant loci (P<5×10−8).(37) However, our previous study was limited to 
European descent populations and cross-sectional analyses, despite many of the contributing 
studies having longitudinal drug and electrocardiographic data.(37) Here, we expand upon 
that work, applying recent statistical innovations to leverage longitudinal data and including 
an additional 44,418 participants of European, African American, and Hispanic/Latino 
descent to perform the first trans-ethnic genome-wide association study (GWAS) to examine 
genetic associations that modify the association between thiazides and QT, as well as the 
component parts of QT (JT interval [JT], QRS interval [QRS]).
Materials and Methods
Study Populations
Fourteen cohorts from in the Cohorts for Heart and Aging Research in Genomic 
Epidemiology (CHARGE)(38) Pharmacogenomics Working Group (PWG) participated in 
this analysis, contributing 78,199 participants: European descent (51,601), African 
American (11,482), and Hispanic/Latino (15,116) participants (Table 1, Supplementary 
Text). Among the fourteen cohorts, six (55% of the total population) had repeated 
measurements of medication use and electrocardiogram (ECG) assessments and contributed 
longitudinal data to the analysis: Age, Gene/Environment Susceptibility – Reykjavik Study 
(AGES), Atherosclerosis Risk in Communities (ARIC) Study, Cardiovascular Health Study 
(CHS), Rotterdam Study (RS), Multi-Ethnic Study of Atherosclerosis (MESA), and 
Women’s Health Initiative (WHI). The remaining eight cohorts contributed cross-sectional 
data to the analysis: Framingham Heart Study (FHS), Erasmus Rucphen Family (ERF) 
Study, Health 2000 (H2000), Health, Aging, and Body Composition (Health ABC), 
Prospective Study of Pravastatin in the Elderly at Risk (PROSPER), Jackson Heart Study 
(JHS), Netherlands Epidemiology of Obesity (NEO) Study, and Hispanic Community 
Health Study/Study of Latinos (HCHS/SOL).
Study Design
Participants with ECG measurements, medication assessment, and genome-wide genotype 
data were eligible for inclusion. The following exclusion criteria were applied: poor ECG 
quality, atrial fibrillation detected by ECG, pacemaker implantation, second or third degree 
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atrioventricular heart block, QRS greater than 120 milliseconds (ms), prevalent heart failure, 
pregnancy, missing ECG, missing medication assessment, missing genotype information, or 
race/ethnicity other than European descent, African American, or Hispanic/Latino. For 
studies with longitudinal data, exclusion criteria were applied on a visit-specific basis.
Medication Assessment
Medication use was assessed through medication inventories conducted during clinic visits, 
home interviews, or through pharmacy databases (Supplementary Table 1). Six studies 
captured medication used on the day of the study visit. A further six of the 14 participating 
cohorts captured medications used one to two weeks preceding ECG assessment. 
HCHS/SOL ascertained medications used within four weeks preceding ECG measurement, 
and the RS captured medication used within 30 days preceding ECG assessment. 
Participants were classified as thiazide diuretic users if they took a thiazide or thiazide-like 
diuretic in a single or combination preparation, with or without potassium (K)-sparing 
agents, and with or without K-supplements.
For cross-sectional studies, the number of exposed participants (Nexposed) was defined as the 
number of participants classified as thiazide users. For studies with longitudinal data, 
Nexposed was calculated as follows:
Nexposed =∑
i
ni
1 + ni − 1 ρ
# Eit = 1
ni
where ni is the number of observations for participant i, ρ̂ is an estimate of the pairwise visit-
to-visit correlation within participants from a Generalized Estimating Equation (GEE)-
exchangeable model that does not contain genetic data, and #{Eit = 1} is the number of 
observations for which participant i was exposed.(39)
ECG Interval Measurement
QT and QRS were digitally recorded by each participating study using resting, supine or 
semi-recumbent, standard 12-lead ECGs (Supplementary Table 2). Comparable procedures 
were used for preparing participants, placing electrodes, recording, transmitting, processing, 
and controlling quality of ECGs. Studies used Marquette MAC 5000, MAC 12, MAC 1200, 
or MAC PC (GE Healthcare, Milwaukee, Wisconsin, USA), University of Glasgow (Cardiac 
Science, Manchester, UK), or ACTA (EASOTE, Florence, Italy) machines. Recordings were 
processed using one of the following programs (Marquette 12SL, MEANS, University of 
Glasgow, Digital Calipers, or Health 2000 custom-made software. JT was calculated by the 
formula: JT=QT−QRS.
Genotyping and Imputation
Each study conducted genome-wide genotyping independently using either Affymetrix 
(Santa Clara, CA, USA) or Illumina (San Diego, CA, USA) arrays (Supplementary Table 3). 
Sex mismatches, duplicate samples, and first-degree relatives (except in ERF, FHS, HCHS/
SOL, and JHS) were excluded. DNA samples with call rates less than 95–98% were 
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excluded, as were SNPs with SNP call rates less than 90–98%, minor allele frequencies 
(MAF) less than 1%, or that failed Hardy-Weinberg equilibrium. To maximize genome 
coverage and comparisons across genotyping platforms, genotypes were imputed using 
HapMap2,(40–42) 1000 Genomes Phase 1, or 1000 Genomes Phase 3 reference panels.(43, 
44) Genotypes imputed using build 37 were lifted over to build 36(45, 46) to enable 
comparisons between imputation platforms and results were restricted to SNPs present in 
HapMap2.
Statistical Analyses
Genome-wide pharmacogenomic analyses were performed by each cohort independently 
across approximately 2.5 million SNPs for QT, QRS, and JT separately. Drug-SNP 
interactions were estimated assuming an additive genetic model, using mixed effect models, 
GEE, or linear regression with robust standard errors. The analytic model varied based on 
study design and the availability of longitudinal data (Supplementary Table 4). All analyses 
were adjusted for age (years), sex when applicable, study site or region, principal 
components of genetic ancestry, visit-specific RR interval (ms), and visit-specific QT 
altering medications defined using the University of Arizona Center for Education and 
Research on Therapeutics (UAZ CERT) QT-prolonging drug classification.(6) Furthermore, 
ERF, FHS, and HCHS/SOL incorporated estimates of relatedness into all analyses. Study-
specific results were corrected for genomic inflation (λ).
Previous simulations demonstrated that models using robust standard errors underestimate 
the variance of coefficient estimates for SNPs with low MAFs.(39) To account for this 
underestimation, corrected standard errors were calculated using a (Student’s) t-reference 
distribution.(39) The degrees of freedom (df) for the t-reference distribution were estimated 
using Satterthwaite’s method.(47) When cohorts were unable to implement Satterthwaite’s 
method, an approximate df was calculated as twice the cohort- and SNP-specific product of 
the SNP imputation quality (range: 0,1), the MAF (range: 0.0,0.50), and Nexposed. Standard 
errors were then “corrected” by assuming a normal reference distribution that yielded the t-
distribution based P-values from the beta estimates.(39) Furthermore, because simulations 
demonstrated that corrected standard errors were unstable when minor allele counts among 
the exposed were low, a cohort-specific df filter of 15 was applied across all SNPs.(39)
For each trait, race-stratified and trans-ethnic betas and corrected standard errors were 
combined with inverse-variance weighted meta-analysis conducted in METAL.(48) We used 
a genome-wide significance threshold of P<5×10−8 and a suggestive threshold of P<5×10−6. 
However, the assumptions of a fixed-effects meta-analysis do not always hold between race/
ethnicities due to differences in patterns of linkage disequilibrium (LD) across ancestral 
populations, potential allelic heterogeneity, differences in gene-environment and gene-gene 
interactions, and differences in environmental and lifestyle factors.(49, 50) Therefore, trans-
ethnic meta-analysis was also conducted using the Bayesian MANTRA approach and a 
genome-wide threshold of log10(Bayes Factor [BF])>6 and a suggestive threshold of 
log10(BF)>5.(51) Additionally, previous studies have demonstrated the potential to increase 
power and detect evidence of pleiotropy by conducting multi-trait analysis across correlated 
traits.(52, 53) To examine potential pleiotropy across ventricular depolarization and 
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repolarization, we conducted cross-phenotype meta-analysis combining t-statistics across 
QRS and JT using an adaptive sum of powered score (aSPU) test, which tests for both 
concordant and discordant associations across some or all of the included traits.(54) The 
reference distribution for the aSPU test was calculated using 108 simulations.
Genome-wide significant and suggestive meta-analysis results were examined for gene or 
pathway enrichment. Previous work has shown that it is beneficial to apply multiple methods 
of gene-set analysis (GSA) when the underlying etiology of the genetic mechanism is 
unclear.(55–57) We therefore used two methods of GSA. We performed a multiple 
regression gene analysis approach followed by a self-contained GSA using gene-level 
regression as implemented in MAGMA.(58) Post-meta-analysis P-values were used as input 
in the analysis and gene-sets were collected from Ingenuity,(59) Panter,(60) KEGG,(61) and 
ConsensusPathDB(62, 63) and restricted to biologically motivated pathways involved in the 
following: ion transport and homeostasis, transcription and translation, renal and cardiac 
development and function, and pharmacokinetic/dynamic pathways. Additionally, we 
selected all SNPs with P<1×10−5 for analysis with DEPICT, which searches for gene, gene-
set, and tissue enrichment among 14,461 reconstituted gene-sets, eliminating the need to 
select candidate gene-sets.(64) To account for multiple testing, we applied a false discovery 
rate (FDR) threshold of 5% for both GSA approaches.
Statistical Power Simulations
Statistical power to detect drug-SNP interactions using cross-sectional and longitudinal 
modeling approaches was estimated via simulation studies. Assumptions, which were 
informed by European ancestry populations, included: (1) 50,000 participants; (2) a two-
sided, per-SNP α=5×10−8; (3) a mean heart rate-corrected QT (standard deviation)=400 (30) 
ms; (4) Nexposed=8,100; (5) a mean drug effect for those with zero copies of the minor 
allele=5 ms; (6) a mean SNP effect for those not exposed to drug=0 ms; (7) a MAF=0.05 or 
0.25; (8) an additive model of inheritance; (9) two study visits for longitudinal simulations; 
(10) within-person QT correlation=0.80; (11) an attrition rate between visits for longitudinal 
simulations=0.13; (12) random missingness rate across study visits=0.09; and (13) an 
independent GEE correlation structure for longitudinal simulations. For longitudinal 
simulations, drug use was either temporally constant or variable. When variable, drug 
exposure was assumed to be completely random at both visits.
Results
Study Characteristics
A total of 78,199 participants were included in the analysis, of which 13,730 (18%) were 
exposed to thiazides (Table 1). Thiazide use was most common among African Americans 
(36%), compared with 16% and 9% among European descent and Hispanic/Latino 
populations, respectively. Mean age ranged from 40 (FHS) to 75 years (PROSPER) and the 
percentage of females ranged from 47% (NEO, PROSPER) to 100% (WHI). Average QT 
was between 389 ms (H2000) and 416 ms (HCHS/SOL).
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Genome-Wide Analysis of Thiazide-SNP Interaction and QT Interval
Q-Q plots for individual study results, as well as for meta-analyzed results, demonstrated 
adequate calibration of study specific test statistics (Supplementary Figures 1–4). However, 
the family-based studies (ERF, FHS, HCHS/SOL) showed modest evidence of over-
dispersion (λ=1.07 – 1.16).
No genome-wide significant thiazide-SNP interaction effects were detected in any race/
ethnic group (Figure 1). However, suggestive interaction effects (P<5×10−6) were found for 
22 loci in at least one race/ethnic group: European descent (seven loci), African American 
(six loci), Hispanic/Latino (six loci), or trans-ethnic (nine loci) (Figure 1, Table 2). Only the 
DNAH8/BTBD9 locus was suggestively significant in more than one race/ethnic group 
(rs862433 in African Americans, rs1950398 in Hispanic/Latinos). Only two of the 
suggestive SNPs were heterogeneous across populations with Phet<0.05 (rs4890550 and 
rs13223427).
Additionally, examination of 35 loci previously associated with QT in a published main 
effects GWAS(65) found no significant associations in European descent populations using a 
Bonferroni corrected threshold of P<0.001 (0.001=0.05/35; Supplementary Table 5). The 
magnitude of the interaction effect was close to zero for all but six of the 35 SNP, which had 
interaction effects greater than 0.50 ms.
Similarly, while no locus showed genome-wide significance in our trans-ethnic MANTRA 
analysis (Supplementary Figure 5), one SNP (rs2765279) was above the suggestive 
threshold, with a log10(BF) of 5.2. Rs2765279, located in RGSL1, a gene involved in G-
protein signaling regulation, was also the most significant SNP in the fixed-effects trans-
ethnic analysis (P=3×10−7).
Genome-Wide Analysis of Thiazide-SNP Interaction and QRS Interval or JT Interval
Results for QRS showed a similar pattern to those for QT (Supplementary Figure 6, 
Supplementary Table 6). Whereas no results achieved genome-wide significance, 28 loci 
showed suggestive evidence of modifying the thiazide-QRS association (four loci in 
European descent populations, 11 in African Americans, eight in Hispanic/Latinos, and 
seven in trans-ethnic populations) and only one SNP had a Phet<0.05 (rs11591185). The 
most significant SNP, rs7638855 (P=2×10−7), located upstream from GAP43, was also 
suggestively significant after trans-ethnic analysis in MANTRA (log10(BF)=5.4; 
Supplementary Figure 5).
Similarly, no SNPs showed genome-wide significant interaction for JT, although 19 loci 
were suggestively associated (five loci in European descent populations, four in African 
Americans, five in Hispanic/Latino, and seven in trans-ethnic populations; Supplementary 
Figure 6, Supplementary Table 7). No SNPs showed significant heterogeneity between 
populations. Moreover, MANTRA analysis identified two SNPs that achieved suggestive 
significance (Supplementary Figure 5). The rs1264878 variant near KCNIP4, a voltage-
gated potassium channel interacting protein was the most significant SNP in our fixed-
effects meta-analyses (P=3×10−7) and had a log10(BF)=5.1. However, most significant SNP 
in MANTRA meta-analyses was rs9303589, in CA10, with a log10(BF)=5.1.
Seyerle et al. Page 6
Pharmacogenomics J. Author manuscript; available in PMC 2018 April 28.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Cross-Phenotype Meta-Analysis
Cross-phenotype meta-analysis found no genome-wide significant evidence of pleiotropy 
across QRS and JT (Figure 2, Supplementary Figure 7). However, eight loci had a 
suggestive evidence of thiazide-SNP interaction after meta-analyzing QRS and JT results 
(Table 3). These included three loci that were nominally associated with QRS and JT 
(P<0.05), but whose effects did not reach the suggestive association threshold in either 
univariate analysis (rs1295230 [PIK3R6], rs6931354 [ADGRB3], and rs8119517 [PREX1]).
Gene and Pathway Enrichment Analysis
Although analysis with DEPICT found no enrichment in a single gene or tissue, gene-set 
enrichment analysis in European descent populations found enrichment in the ATXN3 
subnetwork for the interactive effect of genotype and thiazide use on QT (P=1×10−6). There 
was no enrichment found in QRS or JT analyses. MAGMA analyses found significant 
enrichment in six genes among African Americans in the interactive effect of genotype and 
thiazide use on QRS: CNTRL, CPN1, FAM65B, RAB14, ISY1, NELL1 (Supplementary 
Table 8). No other MAGMA analyses found gene enrichment. MAGMA GSA for QT and JT 
analyses found significant enrichment for transcription and translational pathways, although 
no gene-set enrichment was found in QRS analyses (Table 4).
Statistical Power
Given the biologic plausibility of the suggestive results for all three traits, we examined 
statistical power for our analysis to assess our ability to detect interaction effects. 
Simulations demonstrated that all analyses were underpowered to detect thiazide-SNP 
interaction effects less than 3 ms (e.g. 15% power to detect an interactive effect of 2 ms; 
Figure 3). However, even with time-varying drug exposure (i.e. observed QT measurement 
on and off drug within an individual), which demonstrated the greatest power, analyses for 
SNPs with MAF=5% did not achieve 80% power until the thiazide-SNP interaction effect 
reached 6 ms.
Discussion
In this study, we examined 78,199 participants of European, African American, or Hispanic/
Latino descent for evidence of thiazide-SNP interactions influencing QT. Although we used 
a comprehensive approach that considered multi-ethnic populations, leveraged pleiotropy, 
accommodated population heterogeneity, and examined QT as well as its component parts 
(QRS, JT), we did not identify any genome-wide significant SNPs modifying the association 
between thiazides and these ECG intervals. However, we identified 74 loci with suggestive 
evidence of association through either univariate or cross-phenotype analyses as well as 
evidence of enrichment in pathways involved in transcription and translation.
Interestingly, our suggestive results included multiple loci involved in ion transport and 
handling, the disruption of which is believed to be an underlying mechanism in drug-
induced QT prolongation,(66) supporting the hypothesis that common SNPs modify the 
thiazide-QT relationship. For example, the NELL1 locus was previously associated with 
changes in fasting plasma triglyceride levels in response to hydrochlorothiazide use.(67) 
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Other interesting suggestive results include the PITX2 and RYR3 QRS loci identified in 
Hispanic/Latinos, which may directly regulate ion channel genes and genes involved in 
calcium handling.(68) Moreover, we found suggestive evidence of thiazide-SNP interactions 
on QT, QRS, or JT in other genes involved in ion transport and handling, including STC2,
(69) EDN1,(70) TRPC7,(71) PKP2,(72) and DISC1,(73) as well as a voltage-gated 
potassium channel gene (KCNQ3).
Despite these intriguing results, our power simulations suggested there was limited power to 
detect interaction effects of 2 ms, sizes consistent with QT main effects analyses.(65) The 
low power suggests that larger sample sizes and/or innovative statistical methods may be 
required to study gene-environment interactions given the stringent genome-wide 
significance threshold.(74–76) Furthermore, our power simulations demonstrated 
insufficient power to detect interaction effects of 5 ms or less for less common SNPs 
(MAF=5%). Therefore, future work should utilize larger sample sizes, particularly studies 
with longitudinal data, if available.
Another limitation of our work was that medication use data were collected infrequently, e.g. 
years apart. Particularly, medication assessments covered only one to two weeks of 
medication use in most participating cohorts and variables such as medication dosage and 
duration of use were not available universally across studies. Previous work has 
demonstrated a dose-dependent relationship between thiazide use and cardiac arrest, a 
potential outcome of QT prolongation.(77) However, we were unable to identify participants 
using high dose thiazides because medication dosage data was unavailable in all cohorts. 
Furthermore, K+ measurements and information on K+ supplements was not obtained across 
all cohorts so we were unable to adjust for K+ levels in our analyses, despite the known role 
of thiazide diuretics in inducing hypokalemia and the role of hypokalemia in causing QT 
prolongation.(78, 79)
Furthermore, ECG intervals are known to vary in the presence of cardiovascular disease 
(CVD).(80) While we did exclude participants with certain types of CVD including 
prevalent heart failure and atrial fibrillation, we were not able to further characterize the role 
of CVD in the pharmacogenomics of thiazide use and QT duration. Given that we saw larger 
mean QT and JT intervals in Hispanic/Latino populations than in European descent or 
African American populations in our study sample, as well a substantial difference in mean 
exposure to thiazides, ranging from just 9% in Hispanic/Latinos to 37% in African 
Americans, our analyses are limited by the heterogeneity of exposure and outcome in our 
population. The large difference in thiazide exposure between race/ethnic groups could also 
indicate an underlying difference in CVD prevalence among our populations. Considering 
that pharmacogenomic studies such as this one are already limited in their power to detect 
effects, the addition of unmeasured heterogeneity such as CVD status could further reduce 
our power to detect genetic effects modifying the relationship between thiazides and QT. 
Therefore, future work should consider alternate study designs, such as clinical trials or 
specially collected cohorts, as settings for pharmacogenomics work. In clinical trials or 
specialty cohorts, populations can be more closely controlled and therefore more 
homogeneous in traits that may confound the relationship between thiazides and QT.
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Additionally, observational cohort studies are known to be susceptible to selection biases, 
such as prevalent user bias, whereby long-term medication users are least likely to suffer 
from ADRs and users with ADRs often stop therapy and therefore have a lower chance of 
being seen while on therapy.(81, 82) Unfortunately, without information on duration of use, 
it is difficult to evaluate the effect of prevalent user bias on study results. Indeed, it is unclear 
if these biases are of concern in pharmacogenomic studies.(83, 84) Additional work is 
needed to assess whether selection bias requires more consideration in pharmacogenomic 
research and to assess possible advantages of alternative designs, such as active comparator 
designs (whereby the control group contains participants using a different class of 
medications with similar indications to the medication of interest) or new user designs 
(whereby prevalent users are excluded). Moreover, medication inventories may be associated 
with non-negligible measurement error. For example, while Smith et al. reported good 
agreement between thiazide use measured using medication inventories and serum thiazide 
measurements, specificity remained moderate. (85)
Given the challenges associated with assembling an adequately powered pharmacogenomics 
study, electronic medical records (EMRs) represent a potential untapped resource that may 
merit evaluation. Strengths of EMRs include the potential to provide a more complete 
medication history, which could enable sensitivity analyses examining variables such as 
medication dose and duration of use. Furthermore, consortia such as eMERGE have 
demonstrated the feasibility of linking EMRs to genetic data for use in genetic research,(86) 
and have successfully identified genetic variants modifying drug response.(87) However, 
EMRs have limitations. Investigators using EMR data cannot control participant recruitment, 
timing and accuracy of data collection, or population representativeness.(88) Considering 
ECG research specifically, cohort studies administer ECGs to all participants at study visits, 
whereas EMRs may capture ECGs for patients with medical indications, providing an 
inherently different population. EMRs therefore have the potential to greatly advance 
pharmacogenomic research but warrant further evaluation.
In conclusion, our findings suggest that additional work is needed to fully elucidate potential 
pharmacogenomic effects influencing the thiazide-QT relationship. Our suggestive results 
support a possible role of genetics in modifying the association between thiazides and QT. 
However, these findings can inform the biology of thiazide-induced QT-prolongation and do 
not preclude the possibility of common variants with small effects or rare variants with 
larger effects. Future work that leverages larger sample sizes, such as those available in 
EMRs, and innovative statistical methods to validate these suggestive findings is needed. 
The FDA considers further regulation of drugs that prolong QT by as little as 5 ms, a small 
increment easily achieved by the combination of genetic and pharmaceutical effects,(37, 89) 
making it critical that we unravel the complex etiology of drug-induced QT prolongation.
(90) Pharmacogenomics remain a promising avenue for understanding variability in drug 
response and for utilizing genetics to improve public health but innovative solutions are 
needed to overcome inherent challenges.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. 
Manhattan plots of P-values for thiazide-SNP interaction estimates for QT interval analyses 
after fixed effects meta-analysis among European descent populations (N = 51,601), African 
American populations (N = 11,482), Hispanic/Latino populations (N = 15,116), and all 
populations (trans-ethnic). Each study was analyzed using linear regression, mixed-effects 
models, or generalized estimating equations and SNPs with a study-specific degree of 
freedom measure (df = twice the cohort- and SNP-specific product of the SNP imputation 
quality (range: 0,1), the MAF (range: 0.0,0.50), and the number of individuals exposed to 
thiazide [Nexposed]) < 15 were excluded from meta-analysis. The x-axis represents the 
chromosomal position and the y-axis represents the −log10(P-value). On each plot, genome 
wide significance (P < 5×10−8) and suggestive significance (P < 5×10−6) are denoted with 
dashed lines.
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Figure 2. 
Manhattan plots of P-values thiazide-SNP interaction estimates after cross-phenotype meta-
analysis (QRS interval, JT interval) using aSPU among European descent populations (N = 
47,836), African American populations (N = 11,482), and Hispanic/Latino populations 
(15,116). For each trait separately, each study was analyzed using linear regression, mixed-
effects models, or generalized estimating equations and SNPs with a study-specific degree of 
freedom measure (df = twice the cohort- and SNP-specific product of the SNP imputation 
quality (range: 0,1), the MAF (range: 0.0,0.50), and the number of individuals exposed to 
thiazide [Nexposed]) < 15 were excluded from cross-phenotype meta-analysis. The x-axis 
represents the chromosomal position and the y-axis represents the −log10(P-value). On each 
plot, genome wide significance (P < 5×10−8) and suggestive significance (P < 5×10−6) are 
denoted with dashed lines.
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Figure 3. 
Statistical power of a simulated pharmacogenomics study of QT. The x-axis represents the 
range of tested drug-SNP interaction effects in milliseconds (ms). The y-axis represents the 
power to detect the tested drug-SNP interaction effect. The following assumptions were used 
for the calculations: 2 serial visits measuring electrocardiograms (ECGs) and drug exposure, 
N=50,000 participants, a single-nucleotide polymorphism (SNP) minor allele frequency 
(MAF) of 5% or 25%, and the Nexposed = 8,100. Simulation analyses were run using only the 
baseline visit (cross-sectional) and a longitudinal model. Under the longitudinal model, 
simulations were run with all participants having constant drug exposure across visits or 
having varied drug exposure across visits. Cross-sectional models were run using linear 
regression and longitudinal models were run using a generalized estimating equation with an 
independence working correlation.
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Table 4
Gene-Sets with Enrichment for Genotype-Thiazide Interaction Effects
Trait Population Gene-Set P FDR
QT Hispanic/Latino Nucleotide Binding 5×10−6 0.004
Metal Ion Binding 6×10−6 0.004
tRNA Adenine-N1 Methyltransferase Activity 6×10−5 0.03
Transcription Coactivator Activity 8×10−5 0.03
Transcriptional Activity of SMAD2, SMAD3, SMAD4, Heterotrimer 0.0001 0.03
Zinc Ion Binding 0.0002 0.04
Other RNA Binding Protein 0.0002 0.04
Insulin-like Growth Factor-2 mRNA Binding Proteins (IGF2BPS/IMPS/VICKZS) 0.0003 0.05
Trans-Ethnic General RNA Polymerase II Transcription 4×10−6 0.006
Transcription 4×10−5 0.03
JT African American Transcription Factor TFIID Complex 7×10−5 0.05
Aminoacyl-tRNA Synthetase Multienzyme Complex 0.0001 0.05
tRNA Aminoacylation for Protein Translation 0.0001 0.05
Transcription Factor TFTC Complex 0.0001 0.05
Trans-Ethnic Transciption 3×10−5 0.03
General RNA Polymerase II Transcription Factor Activity 4×10−5 0.03
Abbreviations: FDR, False discovery rate; JT, JT interval; P, P-value; QT, QT interval
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